It’s time we found a cure.
Finding the CURE

CURE, Citizens United for Research in Epilepsy, was founded by parents of children with epilepsy who were frustrated with their inability to protect their children from the devastation of seizures and the side effects of epilepsy medications. Unwilling to sit back and accept the debilitating effects of epilepsy, these parents joined forces to spearhead the search for a cure.

Since 1998, CURE has been at the forefront of epilepsy research, funding more than 130 cutting-edge studies that have resulted in critical breakthroughs in the search for cures for epilepsy. CURE is committed to awarding seed grants for novel research projects that address the goals of “no seizures, no side effects.” Most other agencies can’t or won’t fund such high-risk/high-reward studies due to their preliminary or unconventional nature. CURE understands the need to push the envelope for people with epilepsy.

The success of the CURE Research Program is directly contingent on the support and generosity of our donors. Epilepsy, which affects 1 in 26 Americans in their lifetime, has historically lacked both the focus and resources essential to advance the understanding, treatment and eventual cures for all of the different syndromes that comprise the disease. To that end, CURE is dedicated to investing in the science that will uncover the long-standing mysteries of epilepsy.

Every single seizure has the potential to damage a brain or destroy a life. With your help, we can find the answers we so desperately need. Together, we can find a cure.

1 in 26 people will develop epilepsy in their lifetime.
A LETTER FROM
Susan Axelrod & Bogdan Ewendt

Dear Friends,

It is with pleasure and gratitude that we introduce this Annual Report to highlight our progress and successes and to share hopes and opportunities moving forward.

Neither of us entered the world of epilepsy by choice. Our daughters, Lauren and Samantha, and their relentless struggles with epilepsy are what brought us—and many of you reading this today—to take this on as the fight of our lives.

The esteemed Institute of Medicine issued a report this spring citing that one in 26 Americans will develop epilepsy in their lifetime. One in 26 is a staggering figure and entirely unacceptable when you factor in the destruction and loss of life that epilepsy leaves in its wake. We have theories about why research in this critical area has lagged so far behind, but the important thing is that now, thanks to so many of you, we can point to real progress.

This is not an easy fight. Advances in genetics and imaging are unraveling the mysteries of some of the underlying causes, but there are a multitude of epilepsy syndromes and, therefore, a multitude of solutions waiting to be discovered.

Our growing in-house team works tirelessly every day to accelerate breakthroughs by connecting the research community and by evaluating opportunities through a patient-focused lens. We seek innovative therapies that treat and correct the underlying causes, and we remain steadfast in our commitment to accelerating the advancements that can truly transform lives and ultimately lead to cures.

Every day, countless patients, families, caregivers, scientists, donors and volunteers contribute their time, expertise, energy and passion to help make tomorrow better for all touched by epilepsy and for generations to come.

As the leading non-governmental funder of epilepsy research, we are humbled and proud to be working alongside these champions. Our collective focus and sense of urgency, along with your continued support, will help keep up the momentum and our determination to lift the burden of epilepsy forever.

Sincerely,

Susan Axelrod & Bogdan Ewendt

Board Chair                           Executive Director
Dear Friends:

CURE has inspired the epilepsy research community to redefine and stretch its goals. Thanks to CURE’s advocacy, we no longer accept the status quo—seizures; debilitating treatment side effects; impact on cognition, memory and mood; and loss of life.

As the leading non-governmental agency devoted to funding, catalyzing and driving innovative research, CURE prioritizes the science that will most benefit individuals with epilepsy. This is evident in the studies highlighted in this report.

Efforts are underway to even further revolutionize research by investing in collaborative science designed to eliminate one of the most devastating forms of epilepsy—Infantile Spasms (IS). IS is a syndrome for which a cure, with the proper focus and investment, may be within reach.

It is truly an honor to work with everyone connected to CURE and share in the quest for knowledge that will someday lead to cures for all epilepsy syndromes. Our deepest gratitude goes out to the members of the scientific community whose commitment and generous donation of time and expertise are invaluable.

On a personal note, a generalized tonic-clonic seizure in 2010 was my first symptom of a benign brain tumor, which has been successfully removed. As a person living with the reality of epilepsy, my passion for this cause has intensified, and my enthusiasm for aggressively leading this mission forward has never been stronger. There is enormous comfort and hope in knowing that we are all united in this goal.

CURE Senior Research Advisor
Professor of Pharmacology and Toxicology, University of Utah

---

CURE’s Reach

| 137 grants | 91 institutions | 30 states | 11 countries |

$20 million raised. 83¢ of every dollar invested in research.
CURE Research Highlights

CURE is the leader in the search for a cure, funding more epilepsy research than any other non-governmental agency. We are proud of the many advancements CURE has funded, including the following breakthrough discoveries:

**Annamaria Vezzani, PhD**  
Mario Negri Institute, Milan, Italy  
“Targeting Inflammatory Cytokines for Controlling Seizures”

Dr. Annamaria Vezzani was awarded a CURE grant to support her research into the role of brain inflammation in the progression of epilepsy. Through her work over the past decade, Dr. Vezzani has provided the epilepsy research community with a better understanding of the causes of seizures and epilepsy. Her work is paving the way for future advancements aimed at reducing the occurrence of seizures and preventing the development of epilepsy. Not only did CURE funding play an instrumental role in the discoveries made by Dr. Vezzani, this grant also opened the door to a vast new field of investigation in epilepsy research.

**The Brighter Future Award In Honor of Lauren Axelrod**

**Gary Yellen, PhD and Nika Danial, PhD**  
Harvard Medical School; Dana-Farber Cancer Institute  
“Seizure Resistance through Metabolic Control in Novel Mouse Model”

Drs. Gary Yellen and Nika Danial received a CURE Challenge Award for their efforts to uncover why seizure treatment with drug therapy is more successful when paired with a diet high in fat and extremely low in carbohydrates. The “ketogenic diet,” while proven effective in controlling seizures, is extremely challenging for people to maintain over a lifetime. CURE funding made it possible for Drs. Yellen and Danial to shed new light on the relationship between the ketogenic diet and seizure resistance. Their findings offer an important foundation in the development of a pharmacological substitute for the ketogenic diet to efficiently reduce seizures in epilepsy patients.

**CURE & Dravet Syndrome Foundation Award**

**Scott Baraban, PhD**  
University of California, San Francisco  
“Gene Profiling and High-Throughput Drug Screening in a Zebrafish Model of Dravet Syndrome”

Dr. Baraban received the Challenge Award for his research aimed at developing a drug screening tool to treat Dravet Syndrome, a severe form of pediatric epilepsy. Existing drug discovery programs are not well-designed to address Dravet Syndrome. CURE supported Dr. Baraban’s early efforts to develop this innovative project, which relies on a new method of drug discovery in zebrafish. With CURE’s support, Dr. Baraban was able to obtain critical preliminary data to support his application for a successful National Institutes of Health EUREKA grant. Now, with funds from both sources, Dr. Baraban has been able to expand his project and make further progress in identifying potential new therapies to treat Dravet Syndrome.

* Grants supported through the generosity of individuals, families, foundations or corporations
2011 CURE Research Awards

Acquired Interneuronopathy in a Mouse Model of Infantile Spasms
Sacha Nelson, MD, PhD; Brandeis University

Septohippocampal Stimulation for Seizures and Memory
Robert Gross, MD, PhD; Emory University

Novel Technology to Detect Neurotransmitters During Seizures
Quoc-Thang Nguyen, PhD & Thomas Fouquet, PhD; NeurAccel Biosciences

Seizure Generator Location and Antiepileptic Drug Efficacy
Jeffrey Tenney, MD, PhD; Cincinnati Children’s Hospital Medical Center

Loss of the Perineuronal Net Component of the Extracellular Matrix after Status Epilepticus
Paulette McRae, PhD; Children’s Hospital of Philadelphia

Glia Activation and Vascular Changes as Biomarkers of Epileptogenesis: MRI/MRS Longitudinal Studies in Experimental Models
Teresa Ravizza, PhD; Mario Negri Institute for Pharmacological Research

Julie’s Hope Award*
Flexible, Active, Implantable Devices for Epilepsy
Brian Litt, MD; University of Pennsylvania

CURE & Dravet Syndrome Foundation Award*
Gene Profiling and High-Throughput Drug Screening in a Zebrafish Model of Dravet Syndrome
Scott Baraban, PhD; University of California, San Francisco
People Against Childhood Epilepsy (PACE) Award*
Silencing Hyperactive Neurons as a Treatment for Temporal Lobe Epilepsy
Edward Perez-Reyes, PhD & Jaideep Kapur, MD, PhD; University of Virginia

CJM Foundation Award*
Modulation of Toll-like Receptors to Prevent Post-traumatic Epileptogenesis
Vijayalakshmi Santhakumar, PhD; New Jersey Medical School

The Brighter Future Award*
In honor of Lauren Axelrod, funded by a caring donor
Efficacy of Flupirtine to Treat Hypoxia-ischemia Induced Neonatal Seizures
Yogendra Raol, PhD; University of Colorado, Denver

Lazard Capital Markets Award*
Isoketals as Mediators of Epileptogenesis
Manisha Patel, PhD & L. Jackson Roberts, MD, PhD; University of Colorado, Denver; Vanderbilt University

The 2011 Christopher Donalty & Kyle Coggins Memorial Award for SUDEP Research*
Cardiac Mechanisms of SUDEP in Dravet Syndrome
Jack Parent, MD & Lori Isom, PhD; University of Michigan

The Henry Lapham Memorial Award*
KCNQ Channels in RTN Chemoreceptors
Daniel Mulkey, PhD & Anastasios Tsingounis, PhD; University of Connecticut

The Rock the Block for Pediatric Epilepsy Research Award*
Toward an Innovative Treatment for Pyridoxine-Dependent Epilepsy
Paula Waters, PhD; University of British Columbia/British Columbia Children’s Hospital

The MUSE (Mothers United to Stop Epilepsy) Award*
Simultaneous Electrocorticography and Optical Signal Recording of Seizures in Free-moving Rats with Implantable Device
Hongtao Ma, PhD; Weill Cornell Medical College

* Grants supported through the generosity of individuals, families, foundations or corporations
Luis ("Louie") was a happy, fun-loving kid. He enjoyed playing ball at the park, led a very social life, sang and was in a band. We adored him—everybody did.

Louie’s first seizure came when he was 13. Although he received medication to control them, they were happening every day, which was alarming.

Louie’s seizures caused him to hit his head, break teeth and bruise himself badly. After one particularly bad fall due to a seizure, he even broke his jaw.

Louie’s seizures affected us all. It took a collective family effort to care for him in hopes of minimizing and preventing them from occurring.

As Louie got older, his seizures lessened. However, it seemed like more things would trigger them—if he didn’t sleep enough; missed a dose of medicine; looked at bright lights or sunshine. Louie often felt down about the things he couldn’t do. But he would pick himself up, show off his big smile, and do everything he could to enjoy his life to the max.

We never imagined that, at the age of 24, Louie would leave us. On Sept. 4, 1994, he suffered a fatal seizure. Although Louie is gone, he is forever with us in spirit, as we are with him in finding a cure to end this disease.

-Story told by Luis’s mother, Cristina, and his sister, Tanya, of Chicago

Epilepsy is associated with substantially higher rates of mortality than experienced in the population as a whole.

Source: Institute of Medicine, 2012
CURE RESEARCH

Focus Areas

CURE creates initiatives that address specific problem areas in research, leading the charge to find cures.

CURE Sudden Unexpected Death in Epilepsy [SUDEP] Support

Every year, it is estimated that up to 50,000 deaths occur in the United States from seizure-related causes, including Sudden Unexpected Death in Epilepsy (SUDEP). There is an urgent need for more research to determine the causes of SUDEP so that risks may be minimized and, eventually, eliminated.

34% of all sudden deaths in children are due to Sudden Unexpected Death in Epilepsy (SUDEP).

Addressing this need, CURE established a research program specifically aimed at advancing the study of SUDEP. Since 2004, CURE has funded nearly $1.6 million in research to discover the causes of SUDEP and ways to prevent this devastating occurrence. In addition, CURE has played a leading role in elevating awareness of SUDEP as an important focus area in the study of epilepsy.

Attracting Young Investigators

Statistics show that fewer young people than ever are pursuing careers in the critical fields of science and research. Without the talent, energy and dedication of a new generation of young investigators, our ability to find a cure for epilepsy will be limited. In order to attract these young people, it’s important that we support their journey of scientific discovery.

Responding to this need, CURE initiated the Taking Flight Award for Young Investigators in 2011. CURE awards valued grants to exceptional young researchers. This funding ensures resources for the best and the brightest to potentially make new epilepsy research breakthroughs.

CURE also honors deserving young scientists specializing in the neurosciences with travel awards, which cover transportation and registration costs for the prestigious Gordon Research Conference on Mechanisms of Epilepsy and Neuronal Synchronization (of which CURE is a major sponsor). This conference offers young researchers the invaluable opportunity to interact with leaders in the field.

With this funding, CURE is increasing exciting opportunities for a new generation of young scientists, who will, one day, find the cure we so desperately need to bring an end to epilepsy.
I met my husband Pat at Radford University in 1993. He was athletic, confident and always willing to lend a hand. After graduating, he enlisted in the Army out of love for his country.

Pat deployed to Iraq in June 2006. While on a night mission in Baghdad, he was shot, resulting in a traumatic brain injury.

Since then, Pat has worked hard to regain his ability to walk, talk, write and read. However, the biggest stumbling block has been the post-traumatic epilepsy. I was so frightened when Pat experienced his first seizure four months after his injury; I truly thought he was dying.

Pat has been actively engaged in occupational, speech and physical therapy for five years now. Despite several medications, he continues to experience setbacks and recently suffered a grand mal. I pray this seizure will be Pat’s last but, deep down, I know the odds are against us.

Pat has a lot to keep him going, including a new service dog, me, and lots of opportunities to be a productive member of our community. We try to enjoy what we have and focus on what we can control. Epilepsy definitely does not fit that bill.

-Story told by Pat’s wife, Patty, of McLean, Virginia

For many soldiers suffering brain injury on the battlefield, epilepsy will be a long-term consequence. 53% of Vietnam War veterans with penetrating head injury developed epilepsy.
CURE RESEARCH
Focus Areas (cont.)

Preventing Acquired Epilepsy

Acquired epilepsies—resulting from injury to the brain, including traumatic brain injury, stroke, brain tumor and viral infection (such as meningitis and encephalitis)—are forms of epilepsy that are affecting more and more individuals. Often, a significant lag time occurs between the insult to the brain and the onset of epilepsy, which creates a window of opportunity for intervention to truly prevent epilepsy in these at-risk patients.

The “signature wound” among military service men and women who have served in Iraq and Afghanistan has been traumatic brain injury, of which epilepsy is a common, long-term consequence. Frequently, this chronic condition doesn’t respond to available treatments, creating severe negative effects on rehabilitation and quality of life. The civilian population with head injury, as sustained in car accidents or by athletes, is also at risk. Unfortunately, little is known about post-traumatic epilepsy (PTE) due to a significant lack of research in this area.

Much like PTE, very little is known about why seizures develop in relation to other medical issues such as stroke, infection and tumors. These forms of acquired epilepsy commonly affect older adults—one of the fastest-growing segments of the population with new cases of epilepsy.

CURE strives to push the needle, advancing understanding of acquired epilepsies and its causes. To address this critical research gap, the Prevention of Acquired Epilepsy Award was initiated, urging researchers to seek ways to stop seizures before they start and find better treatment for those who already suffer from an acquired epilepsy.

“CURE played a central role in shaping my career in epilepsy research. Thanks to CURE, I received critical funding when I was just starting my own lab. Working with CURE has allowed me to get to know the real stories of families affected by this disease. Epilepsy became much more than an interesting research question to me—it became my mission. I now feel personally committed to this cause, and CURE has everything to do with it.”

-Daniela Kaufer, PhD, University of California, Berkeley
CURE grantee for Prevention of Acquired Epilepsy research
Research Organizations Supported by CURE Around the World

CURE is proud to have supported researchers at the following esteemed institutions over the years:

Albert Einstein College of Medicine
Barrow Neurological Institute
Baylor College of Medicine
Ben-Gurion University of the Negev
Bogomoletz Institute of Physiology
Boston College
Boston University School of Medicine
Brandeis University
Brigham and Women’s Hospital
British Columbia Children’s Hospital
Case Western Reserve University
Children’s Hospital, Boston
Children’s Hospital of Philadelphia
Children’s Hospital, St. Louis
Children’s Memorial Hospital, Chicago
Children’s National Medical Center
CHU-Sainte-Justine
Cincinnati Children’s Hospital Medical Center
Cleveland Clinic
Dana-Farber Cancer Institute
Dartmouth Medical School
Drexel University School of Medicine
Duke University Medical Center
George Washington University
Great Ormond Street Hospital for Children
Greater Los Angeles VA Medical Center
Harvard Medical School
Helen Hayes Hospital
Hospital for Sick Children
Indiana University School of Medicine
INSERM
IPMC, Nice-Sophia Antipolis
Karolinska Institutet
Ludwig Maximilians University
Mario Negri Institute for Pharmacological Research
Massachusetts General Hospital
Mayo Clinic
McGill University
NeurAccel Biosciences
New Jersey Medical School
New York Medical College
New York University
Northwestern University
Pennsylvania State University
Polytechnic Institute of New York University
Purdue University
RS Dow Neurobiology Lab, Legacy Research
Rush-Presbyterian St. Luke’s Medical Center
Rutgers University
Southern Illinois University School of Medicine
Stanford University School of Medicine
Texas Tech University Health Sciences Center
The Children’s Hospital, Denver
The Hebrew University of Jerusalem
The Jackson Laboratory
The Nathan Kline Institute of Psychiatric Research
The University of Texas Southwestern Medical Center
Toronto Western Research Institute
Tufts University
UCLA School of Medicine
University College London
University Hospital of Wuerzburg
University of British Columbia
University of California, Berkeley
University of California, Davis
University of California, San Francisco
University of Colorado, Denver
University of Connecticut
University of Florida
University of Kuopio, Finland
University of Maryland School of Medicine
University of Melbourne
University of Michigan
University of Minnesota
University of Montana
University of Montreal
University of Pennsylvania
University of Rochester
University of Southern California
University of Sydney
University of Toronto
University of Utah
University of Virginia
University of Washington
University of Wisconsin, Madison
Uppsala University
Vanderbilt University
Wake Forest University School of Medicine
Washington University
Weill Cornell Medical College
Weizmann Institute of Science
CURE EVENTS
Raising Funds & Awareness Coast to Coast

For more than a decade, CURE has hosted the Chicago Annual Benefit, a highly successful fundraiser drawing notable guests and speakers, including political figures, award-winning journalists, musicians and entertainers. CURE has now expanded to other major cities, including New York City, San Francisco and Boston.

In addition, CURE fundraisers come in all shapes and sizes in communities across the country. From dog washes to house parties, dinner auctions to golf outings, these events play a significant role in CURE’s fundraising and awareness efforts. We want to thank all of the individuals and organizations whose remarkable efforts have helped CURE generate vital funds for epilepsy research.
CURE wishes to thank the following individuals and organizations for their remarkable fundraising efforts in 2011:

<table>
<thead>
<tr>
<th>$100,000 and above</th>
<th>White House Correspondents’ Brunch Washington, DC</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>The Everest Art Salon for CURE Chicago, IL</td>
</tr>
<tr>
<td></td>
<td>Gia’s Hope - 3rd Annual Benefit for CURE Miller Place, NY</td>
</tr>
<tr>
<td><strong>$25,000-$99,999</strong></td>
<td></td>
</tr>
<tr>
<td>Drive for CURE 2011 Beach Park, IL</td>
<td></td>
</tr>
<tr>
<td>It’s Time for a Cure: Annual Rhode Island Benefit Harrisville, RI</td>
<td></td>
</tr>
<tr>
<td>Madison Friends of CURE 4th Annual Benefit Madison, WI</td>
<td></td>
</tr>
<tr>
<td><strong>$5,000-$24,999</strong></td>
<td></td>
</tr>
<tr>
<td>Paul’s 5K Run/Walk for Epilepsy Prospect Heights, IL</td>
<td></td>
</tr>
<tr>
<td>Laughing for a Cure Boulder, CO</td>
<td></td>
</tr>
<tr>
<td>Masquerade Benefit for Epilepsy Brunswick, ME</td>
<td></td>
</tr>
<tr>
<td>CURE More Magazine Women’s Half Marathon Team New York, NY</td>
<td></td>
</tr>
<tr>
<td>8th Annual Kyle’s Running for a Memory 5k Run/Walk Pittsford, NY</td>
<td></td>
</tr>
<tr>
<td>Teresa’s Birthday: A Benefit for CURE San Francisco, CA</td>
<td></td>
</tr>
<tr>
<td>John Lawlor Ginger Cove Lake Swim for Charity Valley, NE</td>
<td></td>
</tr>
<tr>
<td>Bag a Bag for CURE 2011 Andover, MA</td>
<td></td>
</tr>
</tbody>
</table>

**Up to $4,999**

- David’s Run 2011 Chesterbrook, PA
- Patrick Ullrich’s 2011 Chicago Marathon Chicago, IL
- “The Dog Days” 2011 Madison, WI
- p.45’s 14th Birthday Celebration for CURE Chicago, IL
- Andy and Patrice’s Wedding Gift Donation Marlboro, MA
- Scoring Goals for CURE: Teamworks Somerset Somerset, MA
- RUN for CURE New York, NY
- Night of Music for CURE & March of Dimes c/o Mya Estes Tampa, FL
- Eli’s Lemonade Stand: 2011 Paul’s Run for Epilepsy Prospect Heights, IL
- Team Jade 2011 Missouri River 340 Kansas City, MO
CURE strives every day to find a cure for epilepsy. By design, CURE does not have an endowment fund, because we feel the funds raised should—and need to—be funneled into studies to find cures. We know that every dollar counts because every seizure matters.

### Statements of Financial Position

<table>
<thead>
<tr>
<th></th>
<th>December 31, 2011</th>
<th>December 31, 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash, Cash Equivalents and Investments</td>
<td>$8,117,892</td>
<td>$5,864,616</td>
</tr>
<tr>
<td>Prepaid Expenses</td>
<td>25,586</td>
<td>26,900</td>
</tr>
<tr>
<td>Contributions Receivable</td>
<td>1,006,292</td>
<td>2,052,944</td>
</tr>
<tr>
<td>Fixed Assets, Net</td>
<td>20,715</td>
<td>15,901</td>
</tr>
<tr>
<td>Security Deposits</td>
<td>8,321</td>
<td>9,741</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td>$9,178,806</td>
<td>$7,970,102</td>
</tr>
<tr>
<td><strong>LIABILITIES &amp; NET ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liabilities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts Payable and Accrued Liabilities</td>
<td>$46,720</td>
<td>$36,954</td>
</tr>
<tr>
<td>Deferred Revenue</td>
<td>-</td>
<td>261,165</td>
</tr>
<tr>
<td>Grants Payable</td>
<td>1,826,339</td>
<td>1,781,985</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td>1,873,059</td>
<td>2,080,104</td>
</tr>
<tr>
<td>Net Assets:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrestricted</td>
<td>6,172,414</td>
<td>4,739,998</td>
</tr>
<tr>
<td>Temporarily Restricted</td>
<td>1,133,333</td>
<td>1,150,000</td>
</tr>
<tr>
<td><strong>Total Net Assets</strong></td>
<td>7,305,747</td>
<td>5,889,998</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES &amp; NET ASSETS</strong></td>
<td>$9,178,806</td>
<td>$7,970,102</td>
</tr>
</tbody>
</table>
Statements of Activities and Changes in Net Assets

<table>
<thead>
<tr>
<th>SUPPORT &amp; REVENUE</th>
<th>December 31, 2011</th>
<th>December 31, 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$2,044,776</td>
<td>$2,034,484</td>
</tr>
<tr>
<td>Special Events</td>
<td>1,988,985</td>
<td>2,406,435</td>
</tr>
<tr>
<td>Investment Income</td>
<td>154,553</td>
<td>289,204</td>
</tr>
<tr>
<td>Miscellaneous Income</td>
<td>1,482</td>
<td>8,413</td>
</tr>
<tr>
<td><strong>TOTAL SUPPORT &amp; REVENUE</strong></td>
<td><strong>$4,189,796</strong></td>
<td><strong>$4,738,536</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EXPENSES</th>
<th>December 31, 2011</th>
<th>December 31, 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Services</td>
<td>$2,312,437</td>
<td>$2,144,646</td>
</tr>
<tr>
<td>Fundraising Expense</td>
<td>261,235</td>
<td>222,705</td>
</tr>
<tr>
<td>Administrative Expenses</td>
<td>200,375</td>
<td>184,626</td>
</tr>
<tr>
<td><strong>TOTAL EXPENSES</strong></td>
<td><strong>2,774,047</strong></td>
<td><strong>2,551,977</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CHANGE IN NET ASSETS</th>
<th>December 31, 2011</th>
<th>December 31, 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net Assets, Beginning of Year</td>
<td>5,889,998</td>
<td>3,703,439</td>
</tr>
<tr>
<td><strong>NET ASSETS, END OF YEAR</strong></td>
<td><strong>$7,305,747</strong></td>
<td><strong>$5,889,998</strong></td>
</tr>
</tbody>
</table>

Efficiency of Expenditures

- Program: 83.4%
- Fundraising: 9.4%
- Administration: 7.2%

Sources of Revenue

- Contributions: 47.5% $1,988,985
- Special Events: 48.8% $2,044,776
- Investment Income: 3.7% $156,035

Totaling: $4,189,796
CURE extends its sincere appreciation for the in-kind donations and services—many year after year—from the following:

AKPD Message and Media
  Special thanks: Larry Grisolano, Deborah Schommer-Klein, Sarah Hegeman & Stephanie Waters
Alario Group
  Special thanks: Ruben Figueres
Andrew Dryer Cinematography, Inc.
ASGK Public Strategies
Botanicals
Bruce Bever Photography
Craftsman
Valerie Davis, MD
Earhole Studios
Filmgear
Haddad Media
  Special thanks: Tammy Haddad & Gretel Truong
Jasculca Terman and Associates
Chef Jean Joho & Tim Anderson
Judy Leisher
Jeffrey Litvack
Karen Lynn
Cyndi Moran
Phil Stefani Signature Restaurants & Events
Ruzicka & Associates, Ltd.
Riordan Sound Services
Sidley Austin LLP
  Special thanks: Lynn Fleisher, Patrick Casey & Michael Clark
Sea Pines Resort
Silverwarre/Curt Silvers
Thomasson Lighting
Walter Payton College Prep Jazz Orchestra
  Special thanks: Glenn Rode
Charles White
Zacuto Camera

“There is no other foundation in America as focused, as driven and with such a unique opportunity to change the course of treatment.”
- Tammy Haddad
  Haddad Media

“I support CURE because of the clarity of its mission, the efficiency of its operations, the fervency of its leaders and the dedication of its supporters. CURE is the exemplar for grassroots fundraising. I am honored to be a part of CURE’s efforts.”
- Lynn Fleisher, PhD, JD
  Sidley Austin, LLP

“I support CURE because it breaks my heart to see what kids with epilepsy have to go through. Just the thought that there could be a cure and we are not focusing enough resources in finding it drives me crazy.”
- Ruben Figueres
  Alario Media
“CURE is critically important because epilepsy, for many years, has been pushed to the back of the line when it comes to funding. This is hard to believe when you consider that 1 in every 26 people will suffer some form of it in their lifetime. CURE knows that epilepsy research, and reaching for the goal of curing it altogether, is essential.”

- The Honorable William M. Daley
The CURE team is small and hardworking. They accomplish so much, wear so many different hats, and all pitch in to achieve our mission—a cure for epilepsy.

-Judy Leisher

Vodafone Americas Foundation
Lally Graham Weymouth
Wilson, Elser, Moskowitz, Edelman & Dicker LLP
Wendy & Richard Yanowitch

$2,500-$4,999

Marc Adelman
Anil Aggarwal
Ellen Alberding & Kelly Welsh
Apollo Data Technologies Health
Ellen Benninghoven & Michael Schafer
Bialkin Family Foundation
David Binder
Blue Shield of California
Heather & Charles Campion
Mr. & Mrs. Richard Cashin
Deborah Kiley & Daniel Cline
David Gallagher Foundation
John Del Cecato
DeVry Inc.
Alicia Dicks
Kathy & Bob Dodd
Mary I. & Philip Doran
East Fordham Management Group, Inc.
Element Professional Staffing
Eugene and Janet Lerner Family Foundation
Fiduciary Trust Company Int’l.
Wendy & Anthony Flammia
Friends of Edward M. Burke
GMMB
Lonny Gold
Marcia Goodstein
Rocio Haas
Jeffrey Hammes
Ben Heywood
Jasculca/Terman & Associates, Inc.
Jocarno Fund
Tracy Kenny
Stephen King
Howard Kirschbaum
Katie Kitchen & Paul Kovach
Soojung Ko
Kyle’s Benevolent Fund
Lefkofsky Family Foundation
Gayle Liebowitz
Masterson Foundation, Inc.
Meckler Bulger Tilson Marick & Pearson LLP
Jill & Paul Meister
MODE Project
Sara & Patrick Nash
Jonathon Niehaus
Nuveen Investments
President Barack & First Lady Michelle Obama
Osterweis Capital Management
Deborah Peacock & Nathan Korn
Questcor Pharmaceuticals, Inc.
Kenneth Raskin
Polly Rattner
Laura & David Ross
Henry Schacht
Luella & Alan Schneider
Jack Sear
Tracy & Lawrence Shar
Kara & Scott Shell
William Singer
Robin & David Small
SNR Denton US LLP
Jeffrey Snyder
Donna & Joel Stender
Stone Shield Inc.
The B & D Foundation
The Malkin Family
The University of California, San Francisco
The Waldman Family Charitable Trust
Susan & Paul Toback
Ungaretti & Harris LLP
Utica National Group Foundation
Carmita & Damon Vaughan
Waggin’ Tails Doggie Dude Ranch
Bruce Waldman
Erin Walsh
Wells Fargo Bank, N.A.
Michael Whouley
Cyndi Wright

$1,000-$2,499

Jim Abrahams
Adams Foam Rubber Company
Aggeus Healthcare, P.C.
American Century Investments Foundation
American Institute of Biological Sciences
Loretta & Walter Anderson
Ariel Investments, LLC
Arthur W. Hill Foundation
Janet & Jack Azagury
Bake’s Steel Erectors, Inc.
Susan & James Bakke
Baltimore Community Fund
Barr Charitable Foundation
Lisa & Stephen Beard
Jason Berry
Maria Botker
Bovis Lend Lease
Barbara & Christopher Brody
Brown & Weinraub, PLLC
Nancy Calcagnini
Gregory Carlin
Castle Harlan Inc.
Sanjay & Bindu Cherian
Chicago Tribune Foundation
Robert Citronberg
Clement’s Market
Steven Clemons
Suzanne & Patrick Coffey
Stanley Cohen
Audrey Colasanti
Sally Csonstos & John Filan
Patti Jo & James H. Cunneen
Cushman & Wakefield of Illinois
Mary Beth Cyze
Dance Yourself Fit LLC
Margaret Daul
Jean D’Amico & David Mark
Patricia & Carl Delbuono
Diana’s Bananas, Inc.
Dimbleby, Friedel, Williams & Edmonds Funeral Homes
Jacqueline & Terrence Doeler
Jeanne & Barry Donalty
Mark Doyle
Joanna & Steven Edelson  
Emery Celli Brinckerhoff & Abady LLP  
EnCana Cares (USA) Foundation  
Barbara & Douglas Engmann  
Epic Systems Corporation  
Epilepsy Foundation of Greater Los Angeles  
Marzena & John Feal  
Jon Fellows  
Shirley & Thomas Hartshorn  
David Heleniak  
Karen Harry & Herb Goldberg  
Vera & J. Mark Hill  
Leo Hindery  
Mary & Michael Holewinski  
Marc Holtzman  
Daniel W. Hynes  
Hynes Law Offices LLC  
Irving Harris Foundation  
Catherine Jones  
Stephen Kabisch  
Mildred & Bernard Kaminsky  
Kasirer Consulting, LLC  
Donna & Steven Katz  
John Kaufman  
Kaye Family Foundation  
Mindy Kefer  
Kelsey Grammer Charitable Foundation  
Caroline Kennedy  
Judy & Jim Klutznick  
Tara & Cary Kochman  
James Kolster  
Steve Lalonde  
Ouriel Lancy  
Burks Lapham  
Lateef Investment Management  
Josh Leavitt  
Karen & William Levis  
Leslie & Karen Lewis  
Mary & Lawrence Liebscher  
Jacqueline Logan & Whitney Magruder  
Margaret Lukens  
Andrea & Thomas Macina  
Dalton Maine  
Daniela Manning  
Donna & John Marino  
Patrice & Francis Marino  
Randy Markowitz, CPA  
Susan & Paul Martin  
Bess-Catherine & James McCord  
McDowell Family Trust  
Colleen & Dan McMahon  
Thomas Meagher  
Medical Cost Management Corporation  
Richard Melman  
Michael Merzenich  
Dana Mikstay  
Luz & Luis Miranda  
Robert Morette  
Morgan Keegan & Company, Inc.  
Julie & Thomas Morin  
Kathy & John Morrissey  
Barb Mosher  
Gregory Mosher  
Julie Munro  
Kristen & Todd Murray  
Newport Division Donuts  
Linda Nolten  
Northwestern Memorial Hospital  
Eleanor & Allan Odden  
Sharon O’Keefe & Hal Moore  
Ostrow Reisin Berk & Abrams Ltd.  
Our Own Roads to Ride, LLC  
P.45, LLC  
Ethel & Peter Parthenis  
Tanya & Rich Patterson  
Greg Paulk  
Stacey & John Pigott  
Dara & Mike Pond  
Joan Pritchard  
Louis J. Ptacek, MD  
R.I. State Council  
Razoo Foundation  
Melissa J. & Peter K. Read

“We support CURE because we all have the same goal—stopping seizures for Hugh and the millions of Americans suffering from epilepsy. CURE supporters are making Hugh better. CURE gives us hope!”

Epilepsy affects more people than multiple sclerosis, cerebral palsy, muscular dystrophy and Parkinson’s disease combined.

* We apologize for any omissions or mistakes. Please contact us to correct our records: info@cureepilepsy.org
My son Jared was six years old when he had his first seizure. I looked at Jared and his eyes were open, but he wasn’t there. I called his name and snapped my fingers. He didn’t move or blink an eye. I knew something was wrong.

At the hospital, Jared was examined and sent for tests, which came back normal. He had suffered what was believed to be a one-time seizure, coupled with an asthma attack.

But one morning a few weeks later, Jared suffered another seizure. Doctors put him on medication, which made him moody and tired. Jared didn’t understand why he had to take pills, why his head often hurt, and why he couldn’t participate in the activities he loves.

Epilepsy has caused so many tears, sleepless nights and countless prayers for the seizures to stop. Miraculously, my prayers were answered. A year ago, his seizures ceased. He still gets painful headaches, but it’s a relief that he is seizure-free right now.

Jared is energetic and active now. He loves to swim, play basketball and is living life to the fullest. However, not everyone is as lucky. When Jared grows up, he wants to be a doctor so that he can help others the way his amazing doctors helped him.

-Story told by Jared’s mother, Tracele, of New York City

More than 40% of patients continue to have seizures despite available treatments, and many of those who obtain seizure control have side effects that are debilitating. CURE’s goal is to enable epilepsy patients to become free of seizures and side-effects.
Donations in Tribute of Those Touched by Epilepsy

Hannah Albus
Sharon Alvarez
Callia Sutcliffe Aman
Lauren Anderson
Jade Andrews
Kathryn Anschutz
Deziree Arguelles
Isabella Armitage
Susan Armstrong
Lynn Atwood
Lauren Axelrod
Susan & David Axelrod
Julia Elizabeth Barnicle
Balarka A. Batabyal
Aine Rose Bautista
Myril Bennett
Cameron Benninghoven
Nicholas Bernstein
Elijah Lawrence Bigelow
Luke Boles
Richard Boswell
Jacob Boyd
Reilly Brennan
Debi & Michael Bronston
Jack Brown
Ella Bull
Olivia Grace Bullis
Alderman Edward Burke
Mary Cahalan
Morgan Campos
Virginia Caranato
Anne Cook Carriere
Peter Michael Carriere
Christopher Cassell
Samuel Chafetz
Jim Claypool
Kyle Coggins
Chris Colfer
Hannah Colfer
George J. Cotsirilos
Shirley Cotzin
Heather Craig
Ansel Culbertson
Gregory Cushman
Nicole Cysimano
Patrice & Andy D’Amore
Michael De Lara
Dan Delfosse
Mr. and Mrs. Raymond Diamond
Stacy Dodd
Casey Donahue
Jeanne & Barry Donalty
Christopher Donalty
Philip Doran
Siina Doran
Luke DuPuis
Andrew Duthaler
Ginny Lee Ellis
Taryn Engstrom
Mya Estes
Michael Faber
Amy Falk
Sarah Ferrone
Anne Finucane
Corrie Fisher
Gia Flammia
Eric Folan
Kimberly Forkum
Alexis S. Forman
David Gallagher
Ed Gerulati
Charlotte Gill
Anthony Giordano
Ben Goldman
Patrice Grant
Adrianna & Matt Greenlee
Mary Gregory
Marge Grossman
Tammy Haddad
Emily Hall
Alice Halldorson
Michael Halldorson
Shay Emma Hammer
Madison Hanosek
Mary Elizabeth Hargett
Ryan Hartman
Christine Haselhorst
Sasson Havusha
Penny Haydar
Michael Healey
Jeanette Hedeman
Paul Heldman
Hailey Helm
Norah Hemani
William A. Hodge, Jr.
Donna Lee Howe
Addison Hutchinson
Henry Iida
Carmen Incera
Abigail Marie Ivie
Zaki Jackson
Michael Johnston
Jacob Jones
Katelynn Jones
Chevelle Lamar Jones
Cori Jordahl
Nicole Wright Jorgenson
Arthur Judd
Elsa Kaim
Susan & Jules Kaufman
Keira Kenny
Tim Kenny
John King
Stephen King
Mary H. Kingsley
Kevin Kleiner
Blanch & Paul Knoebel
Calvin Kolster
Laurie & Paul Lamar
Gardiner Lapham
Henry Lapham
Matthew Larson
Brooke Lawlor
John Lawlor
Kai Leisher
Scott Leisher
Lori Ann Leitzke
The Richard Lienesch Family
David Liner
John Lombardi
Dianne Long
Sheldon Luwick
Walter Averett Lyles
Brandon Mackey
Evan MacPherson
Jenna Malone
David Mark
Daniel Mark
Lauren Marshall
Nichole Martel
Cam McDonald
Colin Michaels
Violet Millay
Sam Miller
Constance Milstein
Mackenzie Moore
Milton Morin
Gregory Mosher
Roberta Mueller
Colleen Mullaney
Ruth Patricia Mullaney
Lilyan Nash
Michael Naskley
Milton Netter
Charles O’Hara
Staci Ojalvo
Eric Osberg
Evie Osberg
Emily Osborne
Clint Osthimer
Todd Parker
James Parrish
Jared Pascarelli
Zach Pfingston
Evan Pigott
Ebony Poindexter
Christine Poulson
Sierra Powell
Jared Prioleau
Eleanor Quindry
Willow Quinn
Odin Rahn
Patrick Rankin
Justin Napier Reed
Adam Regan
Eoin Robertson
James Ruff
Wesley Ryan Rummel
Savannah Salazar
Tiffany Saulters
Herman Schkolnick
Paul Schmidt
Julie Schneider
Mr. & Mrs. Alan Schneider
Susan & James Schneider
Marshall Schneier, Jr.
Harold Schreck
Carolyn Schwarz
Adam Serota
Christy Shake
Lisa and Randy Siegel
Rebecca Siegel
Josh Silverman
Stella Grace Slice
Rebecca Smits
TeamWorks Somerset
Katy Hine Spors
Cody Stender
Gloria Stender
Penny Stender
Marissa Stille
Madison Swallow
Ray Swift
Arlene Swillinger
Kimberly Taube
Cory Taylor
William Thebus
Sam Toback
Adam Todd
Larry Toenjes
Caden Turley
Ella Ullrich
Jackson Jan Vandeberg
Kathleen Brown & Van Sauter
Emily Vaughan
Julie Vehrenkamp Berryhill
The Veins Family
Sam & Beatrice Vogelstein
Rees Volante
Teresa Walsh
Katherine Watson
Maya Weekes
Lally Graham Weymouth
Aloni White
Diane Wilkens
Emily Williams
Lorraine Wishner
Rachel Grey Wolf
James D. Worden
Janet Wright
Jimmie Wrightstone
Eric Wulchin
To date, treatment of epilepsy has been focused on suppressing seizures rather than curing the disorder. With further research it is hoped that symptomatic treatment will be replaced with curative treatment and with prevention strategies.

-Epilepsy Across the Spectrum: Promoting Health and Understanding, Institute of Medicine, 2012
June 5, 2011 was the day that forever changed our lives. This was the day our daughter Alexis was diagnosed with Infantile Spasms, a particularly catastrophic form of epilepsy.

Alexis was born a beautiful, seemingly healthy baby girl. She hit every milestone in her first five months and was full of smiles. We looked forward to her first steps, first words—first everything. In an instant, that anticipation turned to fear—fear of what the future would hold.

The sudden jerks that Alexis began experiencing turned out to be much more than we could have ever expected. Thanks to the experienced doctors and staff at our children’s hospital, Alexis was diagnosed almost immediately. Of course, the diagnosis of epilepsy left us stunned.

Alexis has been through a considerable amount of adversity in her short life, and we have no idea what lies ahead. She has taken numerous medications and has had countless hospital stays. We were finally able to stop the seizures, but Alexis is still very developmentally delayed.

We are so proud of our little girl who still manages to smile every day, even when the odds are against her. Alexis continues to teach us invaluable lessons each day about love, life and determination.

-Story told by Alexis’s parents, Erin and Adam, of Brecksville, Ohio

60% of children with epilepsy face a life of severe cognitive deficits and brain damage leading to a lifetime of illness, disability and dependency.
2011 SCIENTIFIC ADVISORY BOARD

CURE Senior Research Advisor  
H. Steve White, PhD  
University of Utah

Howard Goodkin, MD, PhD  
University of Virginia Medical Center

Louis Ptacek, MD  
University of California, San Francisco

Douglas Coulter, PhD  
University of Pennsylvania

David Prince, MD  
Stanford University

Ivan Soltesz, PhD  
University of California, Irvine

2011 INFANTILE SPASMS ADVISORY COMMITTEE

Anne T. Berg, PhD  
Northwestern University

Daniel Lowenstein, MD  
University of California, San Francisco

Thomas Sutula, MD, PhD  
University of Wisconsin, Madison

Howard Goodkin, MD, PhD  
University of Virginia Medical Center

Jong Rho, MD  
University of Calgary

Annamaria Vezzani, PhD  
Mario Negri Institute

Henrik Klitgaard, PhD  
UCB Pharma

2011 RESEARCH REVIEW COMMITTEE

Individuals touched by epilepsy who serve CURE in an advisory capacity:

Barbara Kelly, Chair  
Tracy Dixon-Salazar, PhD

Stacey Pigott

Valerie Davis, MD, Facilitator  
Jill S. Fischer, PhD

James Schneider, MD

2011 FINANCE COMMITTEE

Thomas F. Hynes, Chair  
Claude Ohanesian

Craig Albert  
Paul Toback
We Need a **CURE** for...